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Mechanisms Potentially
Contributing to the Reduction
in Mortality Associated With
Ticagrelor Therapy*
David J. Schneider, MD
Burlington, Vermont
In this issue of the Journal, Held et al. (1) report the
outcomes of patients who underwent coronary artery bypass
graft surgery (CABG) after being randomly assigned to
clopidogrel or ticagrelor in the PLATO (Platelet Inhibition
and Patient Outcomes) trial. The primary finding of re-
duced cardiovascular and total mortality among patients
who had CABG and were treated with ticagrelor was
directionally consistent but substantially greater (more than
2-fold) compared with that of the parent study (1,2).
Elucidation of the mechanisms contributing to the greater
reduction in mortality in patients who had CABG and were
treated with ticagrelor should advance our understanding of
the role of antiplatelet therapy for patients with acute
coronary syndromes. Because the magnitude of reduction in
mortality was substantially greater and statistically signifi-
cant for cardiovascular mortality, this comment will focus on
potential mechanisms related to cardiovascular outcomes.
See page 672
Unlike thienopyridines (clopidogrel, prasugrel), ticagrelor
is a member of a new class of P2Y12 antagonists that bind
eversibly (3). Reversibility provides flexibility to the patient
nd the provider, allowing more rapid recovery of platelet
unction after the drug is discontinued. More rapid recovery
f platelet function may be a double-edged sword, placing
he patient who is noncompliant at risk of a thrombotic
omplication (e.g., stent thrombosis) at an earlier time point
hen therapy is interrupted. Pharmacodynamic studies have
emonstrated greater antiplatelet effects of ticagrelor com-
ared with clopidogrel as well as greater reversibility (4).
*Editorials published in the Journal of the American College of Cardiology reflect the
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Medicines Company, Sanofi-Aventis, and Bristol-Myers Squibb.he antiplatelet effects seen 3 days after discontinuation of
icagrelor are comparable with those seen 5 days after
iscontinuation of clopidogrel (4).
Greater antiplatelet effects of ticagrelor are unlikely to be
he only mechanism responsible for the greater reduction in
ortality, because greater antiplatelet effects of prasugrel
ompared with clopidogrel were not associated with a
ignificant reduction in cardiovascular mortality (5). A
econd mechanism that appears unlikely to contribute to the
reater reduction in cardiovascular mortality in patients
reated with ticagrelor is an effect on inflammation. Previous
tudies have shown that ticagrelor and clopidogrel have
imilar effects on markers of inflammatory (6).
One rationale for developing a reversible antiplatelet
gent is to reduce the risk of bleeding when surgical
rocedures are required. Bleeding and the transfusion of
lood products have been associated with a greater risk of
eath in patients with acute coronary syndromes (7,8).
oreover, the transfusion of blood products in patients
ndergoing CABG has been independently associated with
n incrementally greater risk of death in direct proportion to
he number of units transfused (9). Although an attractive
otential mechanism responsible for the lower mortality in
atients treated with ticagrelor, bleeding and transfusion of
lood products were similar in patients receiving ticagrelor
nd clopidogrel and undergoing CABG in the PLATO
tudy (1).
One reason for the lack of difference in bleeding compli-
ations was the study design. The protocol stipulated a delay
fter discontinuation of study drug and before CABG of
days for clopidogrel and 1 to 3 days for ticagrelor. The
ifference in intervals reflects the more rapid recovery of
latelet function in patients treated with ticagrelor. In the
LATO study, the study drug was discontinued up to
days before CABG. For patients in whom study drug was
iscontinued 4 days before CABG, mortality was not
ifferent in the 2 groups. Because both drugs would be
xpected to have biological activity up to 4 days after
iscontinuation, these results point to a beneficial effect of
icagrelor, a harmful effect of clopidogrel, or some combi-
ation of the two.
A second potential explanation for a lack of difference in
leeding complications is the stringent definition used to
dentify bleeding complications. Major bleeding was iden-
ified in the majority (80%) of patients who had CABG.
he high frequency of bleeding complications raises the
uestion of whether a definition of bleeding complica-
ions used in other trials and associated with a lower rate
f major bleeding might have identified a difference in
he risk of bleeding in patients treated with either
icagrelor or clopidogrel. Additional evidence in support
f a lack of difference in the 2 groups includes the
ollowing: 1) bleeding events identified by the TIMI
Thrombolysis In Myocardial Infarction) study and the
USTO (Global Use of Strategies to Open Occluded
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Ticagrelor in CABG February 8, 2011:685–7Coronary Arteries) study criteria were similar in the
2 groups; 2) the percentage of patients who experienced a
hemoglobin drop of 3 g/dl or 5 g/dl was similar in the
2 groups; 3) the median number of units of blood transfused
(n  4), the percentage of patients who received transfusion
(52%), and the percentage of patients who received 4
units of blood (16%) were similar in the 2 groups; 4) the
total chest tube output during the first day and the percent-
age of patients with 2 l of chest tube output were similar
n the 2 groups; and 5) reoperation for bleeding was similar
n the 2 groups. Accordingly, a difference in bleeding
omplications does not appear to account for the difference
n cardiovascular mortality between clopidogrel and
icagrelor.
Because the reduction in total mortality in patients
reated with ticagrelor reflected predominantly a decrease in
ardiovascular mortality and because the primary mecha-
ism of action of ticagrelor is to inhibit platelet activation
nduced by the binding of adenosine diphosphate to P2Y12,
otential mechanisms that rely on the primary action of the
ompound should be explored. As mentioned previously, a
ey difference between clopidogrel and ticagrelor is the
eversible binding of ticagrelor. Accordingly, ticagrelor re-
istributes to all platelets in the circulation. Thus, ticagrelor,
nlike clopidogrel, has the capacity to bind to new platelets
s they are released rather than after the next dose of
edication. The redistribution of ticagrelor may contribute
o a reduction in cardiovascular mortality.
The consumption of platelets induced by bleeding,
hrombosis, and hemostasis is a potent stimulus for the
roduction and release of new platelets, primarily
hrough effects of thrombopoietin. Thrombopoietin is
roduced constitutively, and its effects are regulated by its
inding to and subsequent degradation by platelets (10).
he consumption of platelets leads to less degradation of
hrombopoietin, and the greater concentrations of
hrombopoietin stimulates megakaryocytes to produce
ew platelets. Young platelets exhibit increased reactivity
11,12) that may contribute to a greater risk of throm-
otic complications. The redistribution of ticagrelor
ould be expected to attenuate the reactivity of new
latelets more consistently and effectively than clopi-
ogrel. Accordingly, among patients undergoing CABG
n whom bleeding was frequent, the stimulus for new
latelet production is great. The more consistent anti-
latelet effect of ticagrelor because of its reversible
inding may have contributed to a lower incidence of
ardiovascular death. Further, the greater reduction in
ardiovascular mortality by ticagrelor in patients under-
oing CABG is consistent with a greater stimulus for
ew platelet production in these patients.
The transfusion of blood products to patients undergoing
ABG is associated with a greater risk of death. One
echanism by which blood products may promote cardio-
ascular death is by promoting thrombosis. Blood products
uch as packed red blood cells contain activated platelets,latelet-leukocyte aggregates, and microparticles (13,14).
hese components promote thrombosis and may contribute
o cardiovascular death. The reversibility of binding of
icagrelor may attenuate the prothrombotic effect of trans-
used blood products, and thereby reduce the risk of
ardiovascular death in patients who require transfusion.
he reversible binding of ticagrelor provides clinicians with
strategy to address life-threatening bleeding. The trans-
usion of platelets can be used to decrease the antiplatelet
ffects of ticagrelor.
An off-target cardiovascular effect of ticagrelor that may
ontribute to beneficial effects is the inhibition of adenosine
ptake into erythrocytes (15). Greater concentrations in
lood of adenosine appear likely to account for symptoms of
yspnea (16) and may improve cardiac blood flow. Experi-
ental agents that increase endogenous concentrations of
denosine have been show to improve recovery of cardiac
unction after ischemia by reducing the zone of no-reflow
nd the size of the infarct (17). Accordingly, a nonplatelet-
ediated effect of ticagrelor may increase endogenous aden-
sine concentrations that improves myocardial flow and
ecreases the size of myocardial infarcts.
In summary, the outcomes in patients undergoing CABG
n the PLATO trial demonstrate a directionally consistent
ut greater reduction in cardiovascular mortality compared
ith that in the parent trial. Subsequent studies should
ocus on mechanisms responsible for the greater reduction
n cardiovascular mortality to enhance our understanding
nd improve care of patients with cardiovascular disease.
wo characteristics of ticagrelor that merit additional study
re reversibility of its binding to P2Y12 and its inhibition of
adenosine uptake into erythrocytes.
Reprint requests and correspondence: Dr. David J. Schneider,
University of Vermont, 208 South Park Drive, Colchester, Ver-
mont 05446. E-mail: david.schneider@uvm.edu.
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